Business Wire

FL-WELLVII

Share
Wellvii and Care Daily Partner for Health at Home

Wellvii, manufacturer of connected smart devices for health and wellbeing, today announced a partnership with Care Daily, a software technology company with AI-based Caregiver services for senior care, to bring integrated solutions for aging-in-place experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005097/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

myWellvii Platform (Photo: Business Wire)

Patients are now, more than ever, extremely receptive to personal health management solutions. The consumerization and democratization of healthcare gained significant momentum prior to the pandemic and COVID-19 has further accelerated this trend. The partnership between Wellvii and Care Daily will let users take control of their wellbeing with self-monitoring and give them an enhanced view into their overall health.

“The core devices of the myWellvii Platform; the Wellvii MVS1, Wellvii Go wearable, and Wellvii Weight scale in conjunction with the Care Daily’s AI and IoT platform will enable a comprehensive solution for families to measure their health and wellness and improve their well-being.” Mark Khachaturian, PhD CEO of Wellvii.

“Care Daily has commercialized the most advanced AI Caregiver intelligence which, until today, has primarily captured data from ambient sensors in homes to learn lifestyle patterns, trends, and activities of daily living,” said David Moss, CEO of Care Daily. “Integrating Wellvii’s core devices with our AI Caregiver services unifies the lifestyle trends in the home with the biometric trends from the resident’s body, providing an unparalleled understanding of how this person is truly doing. Senior care solutions providers are excited about the opportunity to bring these differentiated services to market under their own brands.”

Both companies are in discussions with major providers to trial the combined technology in homes. Top use cases include senior care and chronic care management.

About Wellvii

Wellvii enables the delivery of healthcare at any address through its all in one comprehensive, clinically validated, connected device that measures 11 vital parameters from the finger, including an oscillometric blood pressure finger cuff. Wellvii also introduces a comprehensive wellness scoring system including the first at-home “stress test” using its proprietary fitness challenge. For more information about the myWellvii platform, click here.

1The Wellvii MVS is not a medical device and cannot be used for clinical applications in the USA. The Wellvii VitalDetect has CE Mark clearance as a Class IIa medical device in Europe. For more information on the Wellvii VitalDetect for Europe, click here. Wellvii has 60 patents issued (57 US, 2 UK, 1 EU).

Follow Wellvii on Twitter, LinkedIn, Instagram, and Facebook.
To directly contact Wellvii: info@wellvii.com.

About Care Daily

Care Daily is the only white-label home health AI and IoT SaaS that deeply personalizes the delivery of senior care through large brands. Care Daily is backed by the NIA, and the company’s award-winning AI Caregiver software intelligence is the first to achieve scientific validation for senior care assistive services in homes. Care Daily’s AI Caregiver personality and services are uniquely configurable by partners for maximum differentiation against other brands and solutions providers. The intelligence detects falls in real-time, uncovers hidden health problems, and brings families and professional caregivers together to care for seniors. Care Daily’s white-labeled solutions are utilized by some of the largest brands to quickly deploy and continually enhance personalized healthcare services for seniors in homes and communities. To learn more, visit www.CareDaily.ai or connect with us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005097/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Approximately 7% of people in the United States (U.S.) have atopic dermatitis – a common, chronic, and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions1-4 While currently available treatments may improve some signs and symptoms of the disease, many patients do not respond optimally to approved therapies and do not experience itch relief and clear skin to the same degree2,5-7 Nemluvio® (nemolizumab) is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and epidermal dysregulation in atopic dermatitis2,9-11 This approval follows Nemluvio’s recent approval for the treatment of adults with prurigo nodularis from the U.S. Food and Drug Administration earlier in August 202412 Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug

Andersen Global forstærker sin dækning af Asien-Stillehavsregionen med ejendomsrådgivere i Australien13.12.2024 19:39:00 CET | Pressemeddelelse

Andersen Global styrker sin platform i Asien og Stillehavsregionen gennem en samarbejdsaftale med Charter Keck Cramer, der er et af Australiens førende, uafhængige ejendomsrådgivningsfirmaer. Det, der i 1970 begyndte som en lille virksomhed, Charter Keck Cramer, har siden udviklet sig til et tværfagligt firma med mere end 170 eksperter, der er fordelt på fem kontorer i Australien og Singapore. Firmaet tilbyder et omfattende udvalg af ejendomsrelaterede ydelser, herunder værdiansættelser inden for bolig- og erhvervsejendomme, ejendoms- og udviklingsrådgivning, ejendomsdata og analyser samt strategisk planlægning og byøkonomi samt kvantitetsopmåling. Charter Keck Cramer betjener en mangfoldig australsk og international kundebase, herunder offentlige og private virksomheder, ejere og udviklere, større banker og finansielle institutioner, institutionelle ejere og truster, statslige organer og familiekontorer. "Vores vækst over de seneste 54 år er drevet af vores uafhængige, skræddersyede t

Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press release

Businesses Must Employ a Multi-Layered Approach to Fight GenAI Fraud Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unli

Capcom Announces Onimusha Way of the Sword, Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press release

Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo

BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press release

BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye